PetIQ, Inc. Provides Unaudited Earnings Guidance for the Year 2017 and Fiscal 2018
January 08, 2018 at 11:07 am
Share
PetIQ, Inc. provided unaudited earnings guidance for the year 2017 and fiscal 2018. For the year, the company expects net sales of $266 million to $267 million, an increase of 33% to 34% year-over-year. Adjusted EBITDA of $21.5 million to $22.5 million, an increase of 103% to 112% year-over-year.
For the initial fiscal 2018, the company expects Pro forma net sales of $450 million to $500 million, an increase of 70% to 90% year-over-year, based on the aforementioned mid-point of PetIQ’s preliminary 2017 unaudited net sales, which reflects elimination of VIP’s sales to PetIQ. Adjusted EBITDA of $40 million to $45 million, an increase of 80% to 105% year-over-year, based on the aforementioned mid-point of PetIQ’s preliminary 2017 unaudited adjusted EBITDA.
PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segmentâs services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.
PETIQ, INC. 
